Clinical Trials Browser

OTHER × Interleukin-2 × 90 days × Clear all

NCT06152809 2026-03-18

CIML NK Cells With Venetoclax for AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT06321484 2026-03-04

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms, Recurrence

NCT07443020 2026-03-02

RIOT 4B

Phase 1 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT00338377 2026-02-23

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma, Meningeal Neoplasms

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase 2 Completed

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT04052334 2026-02-20

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Phase 1 Completed

9 enrolled 10 charts

Sarcoma

NCT07389239 2026-02-20

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06158828 2026-02-13

ABCD-NK

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Phase 2 Recruiting

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06598371 2026-02-11

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT06236425 2026-01-08

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05628883 2026-01-07

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1 Active not recruiting

Uveal Melanoma, Melanoma

NCT06138587 2026-01-02

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute